Close

Actavis (ACT) Made Offer and Still Interested in Deal with Allergan (AGN) - WSJ; Allergan Focuses on Salix Pharma (SLXP) Takeover

September 22, 2014 5:51 PM EDT

(Updated - September 22, 2014 6:08 PM EDT)

Actavis plc (NYSE: ACT) made a bid for Allergan (NYSE: AGN) but was turned away according to reports from the Wall Street Journal, citing people familiar with the matter.

Allergan, which has been fending off a host $53 billion bid for Valeant Pharma (NYSE: VRX), is now in advanced talks to acquire Salix Pharma (NASDAQ: SLXP), according to the report. Allergan rejected Actavis' offer in part because of its focus on a deal with Salix, the report stated.

A deal for Salix Pharma could be valued at more than $10 billion the report said. Salix Pharma is currently in an agreement to merge with a unit of Italy's Cosmo Pharmaceutical.

Meanwhile, Actavis plc is said to still be interested in a deal with Allergan (NYSE: AGN) but only if it is friendly.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Mergers and Acquisitions, Rumors, Trader Talk

Related Entities

Definitive Agreement